The Biotime-backed group believes it can use immune system gene expression levels to detect lung cancer earlier. But another trial will be necessary before the test can…
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.
Sequencing data is all well and good, but what does it mean?
GE arrives to the spin-out party fashionably late.
Can the company's $1.5bn valuation be justified when last year it took just $23.5m in orders?